CAJ | 학술논문

目的研究达美康(格列齐特)联合短效胰岛素腹腔给药在糖尿病肾病腹膜透析患者中的应用综合分析。方法将2001~2013年3月在我院接受腹膜透析治疗的66例终末期糖尿病肾病患者纳入研究，随机分为观察组给予达美康(格列齐特)联合腹腔内用短效胰岛素治疗终末期糖尿病肾病和对照组给予胰岛素腹腔内用降糖治疗。治疗后12w时，比较两组患者的血糖水平、胰岛素用量、肾功能情况以及不良反应例数。结果①治疗后12w时，观察组患者的空腹血糖、餐后血糖、糖化血红蛋白含量、单日胰岛素用量水平均低于对照组，血糖控制达标率高于对照组；②治疗12w内，观察组患者发生腹膜炎、心血管事件、低血糖反应、死亡的例数少于对照组。结论达美康(格列齐特)联合短效胰岛素腹腔用药降糖治疗有助于控制血糖水平、降低胰岛素用量、改善肾功能、减少不良反应发生率，是终末期糖尿病肾病腹膜透析患者理想的降糖方案。
목적연구체미강(격렬제특)연합단효이도소복강급약재당뇨병신병복막투석환자중적응용종합분석。방법장2001~2013년3월재아원접수복막투석치료적66례종말기당뇨병신병환자납입연구，수궤분위관찰조급여체미강(격렬제특)연합복강내용단효이도소치료종말기당뇨병신병화대조조급여이도소복강내용강당치료。치료후12w시，비교량조환자적혈당수평、이도소용량、신공능정황이급불량반응례수。결과①치료후12w시，관찰조환자적공복혈당、찬후혈당、당화혈홍단백함량、단일이도소용량수평균저우대조조，혈당공제체표솔고우대조조；②치료12w내，관찰조환자발생복막염、심혈관사건、저혈당반응、사망적례수소우대조조。결론체미강(격렬제특)연합단효이도소복강용약강당치료유조우공제혈당수평、강저이도소용량、개선신공능、감소불량반응발생솔，시종말기당뇨병신병복막투석환자이상적강당방안。
Objective To observe the application value and Comprehensive analysis combined with short-acting insulin therapy in diabetic nephropathy patients received peritoneal dialysis.Methods 66 cases of diabetic nephropathy patients who received peritoneal dialysis in our hospital from 2001 to 2013.3 were enrol ed and randomly divided into observation group given Diamicron combined with short-acting insulin and control group only given insulin. After 12 weeks of treatment, blood glucose levels, insulin dosage, renal function and cases of adverse reactions were observed. Results ①After 12weeks treatment, fasting blood glucose, postprandial blood glucose, glycated hemoglobin content, daily insulin dosage levels of observation group were lower than those of control group, blood glucose control compliance rate was higher than control group; ②During 12 weeks treatment, cases of peritonitis, hypoglycemia, cardiovascular events, death of observation group were less than those of control group. Conclusion Diamicron combined with short-acting insulin are ideal hypoglycemic therapy in end-stage diabetic nephropathy received peritoneal dialysis for it is helpful to control blood glucose levels, reduce the dosage of insulin, improve kidney function, and to reduce the incidence of adverse events.